Samsung says it's thinking about bringing "vibe coding" to future Galaxy phones, allowing users to describe apps or interface changes in plain language and have AI generate the code. TechRadar interviewed Won-Joon Choi, Samsung's head of mobile experience, to learn more about the plans. Here's an excerpt from their report: As noted by Won-Joon Choi, the usefulness of vibe coding on smartphones is that it opens up the "possibility of customizing your smartphone experience in new ways, not just your apps but your UX." He added, "Right now we're limited to premade tools, but with vibe coding, users could adjust their favorite apps or make something customized to their needs. So vibe coding is very interesting, and something we're looking into." [...]

Samsung recently debuted the Galaxy S26 series of phones and made a point to not call them smartphones -- they're "AI phones" now. This certainly rang true with the majority of upgrades to the devices being AI software-focused, like the new Now Nudge and expanded Audio Eraser tools, with the biggest hardware bump for the base models coming via the 39% improved NPU processing (the processor in charge of on-device AI tasks). It also teased the debut of Perplexity on its phones, joining as an alternative to the Gemini assistant, and teased the possibility of other AI models getting the same treatment in the future.

In February, a six-month-old baby named KJ Muldoon became the first person ever to receive a CRISPR gene-editing treatment customized specifically for his unique genetic mutation, a milestone that researchers say marks a turning point in how medicine might approach the thousands of rare diseases that collectively affect 30 million Americans. Muldoon was born with a type of urea-cycle disorder that gives patients roughly a 50% chance of surviving infancy and typically requires a liver transplant; he is now a healthy 1-year-old who recently took his first steps.

The treatment's significance extends beyond one child. Scientists at UC Berkeley's Innovative Genomics Institute and the Children's Hospital of Philadelphia are now planning clinical trials that would use Muldoon's therapy as a template, tweaking the molecular "address" in the CRISPR system to target different mutations in other children with urea-cycle disorders. Last month, FDA officials Marty Makary and Vinay Prasad announced a new drug pathway designed to accelerate approvals for such personalized treatments -- a framework inspired in large part by Muldoon's case. Current gene-editing delivery mechanisms limit treatments to disorders in the blood and liver. Many families will still go without bespoke therapies.

"It's ridiculous just how virulent some of these bacteria get over time," says Dwayne Roach, assistant professor of bacteriophages, infectious disease and immunology at San Diego State University.

But now CNN says doctors are fighting multi-drug-resistant superbugs with "nature's oldest predators — tiny tripod-looking viruses called phages designed to find, attack and gobble up bacteria." The microscopic creatures have saved the lives of patients dying from superbug infections and are being used in clinical trials as a potential solution to the growing problem of antibiotic resistance...

In labs around the country, phage scientists are taking research and discovery to the next level... [Yale scientists] are busy mapping which phages and antibiotics are most symbiotic in the fight against a pathogen. Roach's San Diego State lab is investigating the body's immune response to phages while developing new phage purification techniques to prepare samples for intravenous use in patients. Currently, clinical trials are underway to test the effectiveness of phages against intractable urinary tract infections, chronic constipation, joint infections, diabetic foot ulcers, tonsillitis and the persistent, reoccurring infections that occur in patients with cystic fibrosis. The chronic infections common in cystic fibrosis are typically due to various strains of drug-resistant Pseudomonas aeruginosa — the same pathogen responsible for Horton's ear infection and the artificial tears outbreak.

A number of labs are developing libraries of phages, stockpiled with strains found in nature that are known to be effective against a particular pathogen. In Texas, a new facility is taking that a step further — speeding up evolution by creating phages in the lab. "Rather than just sourcing new phages from the environment, we have a bioreactor that in real time creates billions upon billions of phages," said Anthony Maresso, associate professor at Baylor College of Medicine in Houston. "Most of those phages won't be active against the drug-resistant bacteria, but at some point there will be a rare variant that has been trained, so to speak, to attack the resistant bacteria, and we'll add that to our arsenal," Maresso said. "It's a next-generation approach on phage libraries." Maresso's lab published a study last year on the treatment of 12 patients with phages customized to each patient's unique bacterial profile. It was a qualified success: The antibiotic-resistant bacteria in five patients were eradicated, while several more patients showed improvements.

"There's a lot of approaches right now that are happening in parallel," Roach said. "Do we engineer phages? Do we make a phage cocktail, and then how big is the cocktail? Is it two phages or 12 phages? Should phages be inhaled, applied topically or injected intravenously? There's a lot of work underway on exactly how to best do this...." Genetically engineering phages would allow scientists to target each person's unique mix of antibiotic-resistant pathogens instead of searching sewage, bogs, ponds, the bilge of boats and other prime breeding grounds for bacteria to find just the right phage for the job.

Along with phage libraries, genetic engineering is also a key to churning out phages in mass, to distribute on a wider scale. In Russia and the country of Georgia, where phage therapy has been used for decades, patients can buy phage cocktails off the shelf in pharmacies.

A group of researchers at University College London (UCL) have used an MRI scanner to guide a tiny magnetic "seed" through the brain to heat and destroy cancer cells. Interesting Engineering reports: The novel breakthrough cancer therapy, which has been tested on mice, is called "minimally invasive image-guided ablation," or MINIMA, according to the study published in Advanced Science. It consists of ferromagnetic thermoseeds, which are basically 2mm metal spheres, that are guided to a tumor using magnetic propulsion generated by an MRI scanner and then remotely heated to kill nearby cancer cells. If this technique translates to humans, it could help to combat difficult-to-reach brain tumors by establishing "proof-of-concept" for precise treatment of cancers like glioblastoma, the most common form of brain cancer, and prostate, which could benefit from less invasive therapies.

The UCL researchers demonstrated the three major components of MINIMA to a high level of accuracy: precise seed imaging, navigation through brain tissue using a customized MRI system (tracked to within 0.3 mm accuracy), and eradicating the tumor in a mouse model by heating it. The researchers used an MRI machine to direct 2mm diameter metal spheres, which were implanted superficially into the tissue, then navigated to the tumors. Then, they were heated to destroy the cells. "Using an MRI scanner to deliver a therapy in this way allows the therapeutic seed and the tumor to be imaged throughout the procedure, ensuring the treatment is delivered with precision and without having to perform open surgery," explained lead author Rebecca Baker at the UCL Centre for Advanced Biomedical Imaging, in a press release. "This could be beneficial to patients by reducing recovery times and minimizing the chance of side effects."

Emily Mullin reports via MIT Technology Review: Now two personalized cancer vaccine approaches appear to have safely prevented cancer relapse in a dozen patients with late-stage skin cancer. In recent years, scientists have realized that each patient's tumor harbors a unique set of genetic characteristics, or mutations. So for cancer vaccines to be effective, they'll probably also have to be unique. Two clinical trials, detailed today in separate papers in Nature, are among the first to show that this might be possible. In one trial, eight of 13 melanoma patients who got a personalized cancer vaccine were tumor-free nearly two years after being treated. In a smaller study, four of the six patients who received a vaccine had no detectable cancer for more than two years after treatment. All patients had their tumors surgically removed before getting the vaccine. The customized vaccines are an emerging class of therapies that take advantage of neoantigens, proteins that appear on tumors and seem to be specific to each cancer patient. To make the vaccines, researchers first sequenced DNA and RNA extracted from each patient's tumor. They then used computer algorithms to analyze the mutations on each tumor and predict the best targets that code for neoantigens. Based on that data, they created a personalized vaccine containing up to 20 of these neoantigens. Each patient received several injections of the vaccine over a few months.

randomErr writes: 5.7 million adults in the United States have heart failure each year with about 41 million worldwide. Currently, treatment involves surgically implanting a mechanical pump, called a ventricular assist device (VAD), into the heart. The VAD helps maintains the heart's function. But patients with VADs are at high risk for getting blood clots and having a stroke. Researchers at Harvard University and Boston Children's Hospital have created a soft robotic sleeve that doesn't have to be implanted. The robotic sleeve slips around the outside of the heart, squeezing it in sync with the natural rhythm. "This work represents an exciting proof of concept result for this soft robot, demonstrating that it can safely interact with soft tissue and lead to improvements in cardiac function," Conor Walsh, said in a press statement. Seeker reports: "The sleeve they developed is made from thin silicone and attaches to the outside of the heart with a combination of suction devices and sutures. It relies on soft, air-powered actuators that twist and compress in a way that's similar to the outer layer of muscle of a human heart. A gel coating reduces any friction between the sleeve and the organ. Because the sleeve is soft and flexible, it can be customized to fit not just the size and shape of individual hearts, but augment the organ's weaknesses. For example, if a patient's heart is weaker on the left side than the right, the sleeve can be tuned to squeeze with more authority on the left side. As the organ gains strength, the device can be adjusted." The study has been published in the journal Science Translational Medicine.

First time accepted submitter Leslie Oliver Karpas writes As millions of Americans with Obstructive Sleep Apnea struggle to get a good night's sleep, one company has harnessed 3D technology to revolutionize CPAP therapy. As 3ders.org reported today, "Metamason is working on custom CPAP masks for sleep apnea patients via 3D scanning, smart geometry, and 3D printing." "We're at the crossroads of 3D technology and personalized medicine," says Metamason's founder and CEO. "There are many medical products that would be infinitely more comfortable and effective with a customized fit. CPAP therapy is the perfect example—it's a very effective treatment with a 50% quit rate, because mass-produced masks are uncomfortable and don't fit properly." CPAP is a respiratory device worn during sleep to treat OSA, which affects 1 in 4 men and 1 in 9 women in the US alone. Metamason's "ScanFitPrint" process for creating their custom Respere masks translates a 3D scan of the patient's face into a 3D printed custom mask that is a perfect individual fit. To print the masks in soft, biocompatible silicone, Metamason invented a proprietary 3D printing process called Investment Molding, which creates wholly integrated products that were previously considered "unmoldable."

itwbennett writes "Google has done what the European Commission declined to do: publish the details of the latest commitments Google made in a bid to settle a long-running antitrust case involving its treatment of rival specialist search services, among other matters. On the company's European policy blog, Google's senior vice president and general counsel, Kent Walker, announced the publication of what he called the 'full text' (PDF) of the company's commitments. In fact, the 93-page document contains a number of redactions, including details of a parameter used to rank search results, the identities of two companies with customized contracts for Adsense For Search, and a proposal for modification of those contracts to comply with the other commitments."

A long, long time ago, you asked questions of Mark Shuttleworth -- astronaut, entrepreneur, activist, and now chief of Debian-and-GNOME based distribution Ubuntu Linux. Mark's been understandably busy running the world of Ubuntu, especially considering the imminent release of the group's newest version, Hoary Hedgehog. He's answered below questions on everything from what makes it worth paying for a trip to space to how software offered with source, for free, and under a liberal license (aka Free software) can sustain itself and its creators. Read on for his answers.